RBC Capital analyst Randall Stanicky reiterated an Outperform rating and $12 price target on Kempharm (NASDAQ: KMPH) noting attention is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE